Hypertension and cardiovascular disease remain the major causes of premature morbidity and mortality. Following a diagnosis of hypertension, treatment with antihypertensive medication will almost invariably be lifelong. Even when prescribed treatment, many patients remain above blood pressure goals, and this is particularly common in patients at high risk of cardiovascular events due to the presence of other risk factors such as diabetes mellitus. An important cause of this failure is medication nonadherence, which is particularly common with treatments that have side-effects. Antihypertensive drugs do not make the patient feel better in the short term, but side-effects often occur immediately. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) is highly relevant to clinical practice because it demonstrated that the angiotensin receptor blocker (ARB) telmisartan is as effective as the proven angiotensinconverting enzyme inhibitor ramipril in preventing cardiovascular events in highrisk patients, while being better tolerated. Evidence of the advantages of telmisartan in the management of cardiovascular morbidity suggest, therefore, that it might be a better treatment option for hypertensive patients and that switching to generic ARBs may not always be best.
Introduction
It is remarkable that, as recently as the 1960s, a study showing the benefits of treatment of diastolic blood pressure (DBP) at levels of 115 -129 mmHg or above was considered groundbreaking. 1 Since then, many trials have shown the benefits of treatment of less extreme degrees of hypertension. The Framingham trial demonstrated three important principles about the relationship between blood pressure (BP) risk and cardiovascular disease (CVD): (i) the risk is continuous, with a higher cardiovascular risk accruing from a BP of 140/90 mmHg than from an optimal ≤ 120/80 mmHg; (ii) raised BP is not a 'natural' or benign consequence of aging, but a disease process, with older patients being at a higher risk at any given BP; and (iii) systolic blood pressure (SBP) is a more accurate predictor of cardiovascular risk than diastolic blood pressure (DBP). 2 Many studies have been performed, providing sufficient evidence for meta-analyses S Jarvis Angiotensin receptor blockers in clinical practice confirming the closer correlation between SBP than DBP for cardiovascular risk. 3 Hypertension is known to have a major impact on the incidence of stroke -for every 10 mmHg increase in baseline SBP there is a 12% increase in stroke and an 8% increase in cardiovascular events, compared with a 4% increase in coronary events. 4 When coronary heart disease patients from the EUROpean Action on Secondary Prevention through Intervention to Reduce Events (EUROASPIRE) study were analysed for the relative importance of a variety of risk factors for cardiovascular death, SBP was significantly associated with increased cerebrovascular mortality with a hazard ratio of 1.04 (95% confidence interval [CI] 1.01, 1.08) for every 1 mmHg increase. 5 This compared with a coronary heart disease mortality hazard ratio of 2.36 (95% CI 1.31, 4.24) for patients with diabetes mellitus. 5 Although elderly patients with elevated BP are routinely treated to similar levels as their younger hypertensive counterparts, it is only in the last 3 years that definitive proof has emerged of the benefits of tight BP control on mortality as well as morbidity in people aged > 80 years. 6 There is some controversy regarding the optimal target BP in patients with diabetes, but a metaanalysis of available outcome studies offers compelling evidence that the optimal BP for these patients is in the region of 130 -135 mmHg, and even lower for patients at particular risk of stroke. 7 There is a continuing need for more good data and more effective ways of managing hypertension and cardiovascular risk.
Prevalence of hypertension is high but control is poor
The prevalence of hypertension varies worldwide, ranging from 3.4% in men and 6.8% in women in rural India to 68.9% in men and 72.5% in women in Poland (compared with rates of about 39% in England). 8 Rates of awareness (25 -75%) and treatment (11 -66%) of hypertension also vary widely. 8 The level of hypertension control (to ≤ 140/90 mmHg) is not consistent, with 29.2% in England, 5.4% in Korea and 58.0% in Barbados -the country with the best control rate. 8 In addition, despite ample evidence that SBP is more important than DBP in reducing cardiovascular morbidity and mortality, several studies have shown that SBP is, on average, less well controlled than DBP. 9 In the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT), for example, while DBP was controlled in 92% of patients, only 67% of patients achieved target SBP control with aggressive treatment. 10 While the relative risk with rising BP is consistent and predictable, the absolute risk depends on increasingly common interdependent factors, including increased age, diabetes, sedentary lifestyle, dyslipidaemia and obesity. 11 Patients with multiple risk factors are at an extremely high risk of CVD, 12 but are historically undertreated. 13 Having different targets for patients with differing conditions (e.g. < 140/85 mmHg for patients with uncomplicated hypertension, < 130/80 mmHg for patients with chronic kidney disease or diabetes/ cardiovascular disease), 14 as well as an under-recognition of the increased risk associated with having multiple risk factors or disease in more than one vascular bed, 15 may contribute to this under-treatment.
Why treatment nonadherence is to blame
Much of the reason for poor BP control relates to poor adherence to medication. The 1-year continuation rates for antihypertensive agents in a cohort study of 21 723
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patients newly initiated on antihypertensive treatment were: angiotensin receptor blockers (ARBs), 64%; angiotensinconverting enzyme (ACE) inhibitors, 58%; calcium antagonists, 50%; β-blockers, 43%; and thiazide diuretics, 38%. 16 Decline in treatment adherence may continue even after patients have persisted with treatment during the first year. For example, in a 4year retrospective cohort study of 15 175 hypertensive patients from a wide geographic and demographic spectrum, persistence declined steadily from 12 to 48 months after initiating therapy. 17 By the end of 4 years, 43.3% were not taking any antihypertensive medication, with a discontinuation rate of around half for patients initially treated with a β-blocker or thiazide diuretic. 17 Discontinuation rates were lowest for ARBs (32.7%) and highest for β-blockers (52.6%). 17 Among patients treated with drugs other than ARBs, 63.5% had either discontinued (20.0%) or switched (43.6%) antihypertensive medication within 4 years. 17 A recent meta-analysis of 17 studies suggested that adherence to ARBs may be 30% greater than adherence to ACE inhibitors and twice that of diuretics or βblockers. 18 Even among patients who persist with their medication, compliance is not as straightforward as one might imagine. The most common problems are missed doses and prolonged intervals between doses, but they also include 'white coat compliance' (taking medication only in the run-up to appointments). 19, 20 In one study, half of patients changed their medication because of adverse events and patient dissatisfaction, almost exactly the same number who changed because of inadequate BP control. 20 A study of community-living older people found that half would refuse a medication that reduced 5-year cardiovascular risk from 20% to 12% if it caused daily fatigue and dizziness. 21 It has been proven that patient adherence correlates inversely with the number of sideeffects. 22 
Improved treatment efficacy and tolerability may improve control
When patients are diagnosed with hypertension and started on antihypertensive medication, treatment will almost invariably be lifelong. Antihypertensives, like most preventive medications, do not make the patient feel better in the short term, but side-effects often occur immediately. The diagnosis is accompanied by an irreversible 'disease label' and the prospect of taking one, and often more, medications with no immediate benefit -> 60% of patients in the ALLHAT study required multiple medications to control their BP. 10 If patients take their medication in the run-up to appointments, 20 doctors may be unaware that their overall adherence is poor and may, therefore, underestimate the scale of the problem. If adherence rates are to be improved, patients must understand the adverse implications of not taking medication regularly and medication should be tailored, not only to control BP adequately over the whole 24-h period, but also to minimize side-effects.
The recent update of the National Institute for Health and Clinical Excellence (NICE) guidelines recommends calcium channel blockers over and above thiazidetype diuretics as first-line therapy for most patients > 55 years of age and Black patients of any age, in contrast to the previous guidelines in which either class of drug was recommended equally as a first step. 23, 24 The NICE 2011 guidelines recommend that ARBs S Jarvis Angiotensin receptor blockers in clinical practice (of low acquisition cost) should be considered as an equal first-line option alongside ACE inhibitors in patients aged < 55 years, and as an alternative treatment for those initiated on ACE inhibitors who are unable to continue therapy due to intolerance. 24 The most common cause of ACE inhibitor intolerance is cough, which affects 5 -35% of patients. 25 Clinical trials have found that both the incidence of cough and withdrawal rates due to cough with ACE inhibitors are substantially greater than those reported by the Physicians Desk Reference. 26
Reducing cardiovascular risk -beyond blood pressure effects
The ACE inhibitors have been available for significantly longer than ARBs, 27 and have a large body of trial evidence to support their efficacy in reducing both BP and cardiovascular morbidity and mortality. 20 They are also almost all available in generic form and are thus significantly cheaper than most ARBs. This was almost certainly a factor in the decision by NICE to recommend them above the newer and better tolerated ARBs, unless the ARBs are of low acquisition cost. In addition, there have been few large head-to-head studies comparing the effects beyond BP lowering on hard outcomes in patients treated with ACE inhibitors versus ARBs; 28 and until recently there was some controversy over whether ARBs increase the risk of myocardial infarction (MI) compared with ACE inhibitors. 29 This controversy has been compounded by results from the Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) trial in patients without hypertension but with diabetes and additional risk factors. 30 In this study, deaths from cardiovascular causes were significantly higher with olmesartan (n = 15, 0.7%) than with placebo (n = 3, 0.1%; hazard ratio [HR] 4.94; 95% CI 1.43, 17.06; P = 0.01), although deaths from any cause were not significantly different (26 [1.2%] patients versus 15 [1.7%] patients, respectively; HR 1.70; 95% CI 0.90, 3.22; P = 0.10). 30 A similar excess cardiovascular mortality with olmesartan was seen in the Olmesartan Reducing Incidence of ENd stage renal disease in diabetic Nephropathy Trial (ORIENT). 31 The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) examined the safety and efficacy of telmisartan. 32 This trial used a similar population and design to that of the Heart Outcomes Prevention Evaluation (HOPE) study 33 to demonstrate that the ARB, telmisartan, was as effective (noninferior) as the ACE inhibitor, ramipril, in preventing vascular events, such as stroke and MI, in high-risk patients who had cardiovascular disease or diabetes but did not have heart failure. 32 This equivalent efficacy in preventing cardiovascular events was achieved despite the fact that BP reductions were similar (due to the use of concomitant antihypertensives) and patients were screened for ACE inhibitor tolerance, and was consistent across all outcomes (including MI). 32 The ONTARGET results are important for several reasons. First, the HOPE study was a landmark study, which shaped national and international guidelines for the management of hypertension. The American College of Cardiology (ACC)/American Heart Association (AHA) 2002 guidelines for the treatment of stable angina, for instance, state: "The results of HOPE were extremely impressive when one considers the magnitude of the difference between ramipril and placebo in the primary outcomes of cardiovascular death, MI, and S Jarvis Angiotensin receptor blockers in clinical practice stroke". 34 Secondly, the study results were convincing enough for telmisartan to become the only ARB licensed by regulatory bodies for the reduction of cardiovascular events in a broad group of high-risk patients. The European Medicines Evaluation Agency (EMEA) has approved telmisartan for the reduction of cardiovascular morbidity in a broad population of high-risk patients (manifest atherothrombotic cardiovascular disease [history of coronary heart disease, stroke, or peripheral arterial disease] or type 2 diabetes mellitus with documented target organ damage), while the United States Food and Drug Administration (FDA) has approved telmisartan for the reduction of the risk of MI, stroke, or death from cardiovascular causes in patients 55 years or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors. Thirdly, the ONTARGET study was the first major study to compare an ACE inhibitor with an ARB in a wide population, even though several other studies comparing ACE inhibitors with ARBs had shown ARBs to be noninferior or superior in patients with heart failure. 28, 35 This benefit is perhaps not surprising -local angiotensin II concentration is increased in heart failure, with a direct correlation existing between levels of cardiac angiotensin II release and clinical severity of heart failure. 36 The efficacy of ARBs varies, however, even in treating heart failure. For example, noninferiority was not confirmed in two trials comparing losartan 50 mg daily with captopril 50 mg three times daily, 37, 38 but was confirmed in a trial of post-MI patients with heart failure, left ventricular dysfunction or both, which compared valsartan 160 mg twice daily with captopril 50 mg three times daily. 35 Higher doses of losartan (150 mg/day) are, however, more effective in treating heart failure 39 although, in most countries, the only licensed doses of losartan are 50 and 100 mg daily. In the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial, the addition of candesartan (up to 32 mg daily) to a variety of ACE inhibitor therapies in patients with heart failure reduced cardiovascular mortality (regardless of other treatments). 40 On the other hand, in the Valsartan Heart Failure Trial (Val-HeFT), the addition of valsartan 160 mg twice daily to ACE inhibitor and β-blocker therapy increased mortality. 41 There are clinically significant differences between the ARBs. In a meta-analysis of 24 h BP reduction with ARBs, losartan, valsartan and eprosartan were the least effective. 42 Telmisartan has been shown to provide significantly better control of 24-h BP than losartan (as measured by ambulatory BP monitoring) 43 and, in patients with diabetic nephropathy, telmisartan reduced progression of mean urine protein : creatinine by 29.8%, significantly more than losartan (21.4%). 44 The rate of treatment discontinuation for losartan was found to be higher than for other ARBs, 45 perhaps as a result of its lower efficacy.
Conclusions
Losartan was the first generic ARB to become available, and general practitioners in the UK are under pressure to choose it as the cheaper option. In contrast to the statins, where 8 years passed between simvastatin and the next more effective statin coming off patent, four other ARBs will be available in generic form within 4 years. The cost savings are, therefore, likely to be small and there may be both a clinical disadvantage to patients and a financial cost if primary care physicians do not reach BP targets. The ONTARGET study provides increasing evidence of the advantages of telmisartan in the management of cardiovascular morbidity, suggesting that it might be a better treatment option for hypertensive patients and that switching to generic ARBs may not always be best.
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